Cofoe Medical Technology Co., Ltd. (Ticker: 1187 HK) is a Chinese company focusing on the manufacturing and distribution of home care medical devices, such as glucose meters, blood pressure devices, wheelchairs and hospital beds.

Cofoe Medical Technology plans to list on the Hong Kong Exchange on May 6, 2026, planning to offer 27.0 million shares at an expected price of HKD 39.33, raising approximately HKD 1.06 billion (USD 135.5 million). According to published terms, BNP Paribas Securities Asia, Futu Securities International, and Huatai Financial Holdings are serving as the joint managers for the IPO.

As reported in the prospectus, the firm ranked second among home care medical device providers in China based on 2024 domestic revenue, capturing a 2.1% market share in a highly competitive sector. The company operates an integrated research, development, manufacturing, and distribution model. Its extensive product portfolio addresses diverse healthcare scenarios and encompasses over 200 categories with more than 10,000 SKUs. While the Chinese mainland represents its primary geographic segment, Cofoe Medical Technology is actively expanding its sales footprint into international markets, including Hong Kong, the United States, and the United Kingdom.